Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.6K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.4K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Minimally Invasive Porcine Model for Chronic Thromboembolic Pulmonary Hypertension.

Pulmonary circulation·2026
Same author

Ventilatory Efficiency During Exercise in CTEPH and PAH Pre- and Post-Treatment.

Pulmonary circulation·2026
Same author

Pleural Infection in Adults: Integrating Medical and Surgical Management for Optimal Outcomes.

Thoracic surgery clinics·2026
Same author

Correction: Prisciandaro et al. Anatomical Versus Non-Anatomical Pulmonary Metastasectomy: European Multicentre Analysis. <i>Cancers</i> 2026, <i>18</i>, 1037.

Cancers·2026
Same author

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Donor-recipient sex differences: Implications for immunologic outcomes but no impact on survival after lung transplantation.

JHLT open·2026

相关实验视频

Updated: Jan 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

关于新辅助剂和辅助剂试验的最新情况

Raphael S Werner1, Nina Steinmann1, Isabelle Opitz2

  • 1Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

Thoracic surgery clinics
|November 19, 2025
PubMed
概括

免疫检查点抑制剂与化疗相结合,改善了非小细胞肺癌 (NSCLC) 的结果. 对个性化治疗选择和降级策略需要进一步的研究.

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 癌症研究 癌症研究

背景情况:

  • 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
  • 新辅助和术后免疫疗法与化疗相结合,代表了NSCLC治疗的重大进步.
  • 这些组合疗法已经显示出改善了病理反应和生存结果.

研究的目的:

  • 总结最近在NSCLC的新辅助和外科手术期间免疫疗法的进展.
  • 突出这些治疗对反应率和生存率的影响.
  • 讨论正在进行的研究方向,包括生物标志物开发和治疗降级.

主要方法:

  • 对标志性III期临床试验的审查,评估NSCLC中的免疫疗法加化疗.
  • 对完整反应率,无事件生存率和整体生存率的数据进行分析.
  • 讨论当前的研究,探讨治疗优化和个性化医疗方法.

主要成果:

  • 组合疗法显著增加了NSCLC的完全响应率.
  • 无事件和整体生存时间延长,特别是在具有编程死亡连接体1 (PD-L1) 阳性瘤的患者中.
  • 目前正在进行的研究正在调查辅助免疫疗法和循环瘤DNA (ctDNA) 作为预测生物标志物.
关键词:
临床试验中的临床试验.免疫治疗是一种免疫疗法.肺癌是一种肺癌.新辅助剂是一种新辅助剂.经期操作性 经期操作性ctDNActDNA是什么意思

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

相关实验视频

Last Updated: Jan 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.7K

结论:

  • 免疫检查点抑制剂与化疗正在改变局部晚期NSCLC的管理.
  • 进一步的研究对于完善患者选择和开发预测生物标志物至关重要.
  • 个性化治疗策略和缓解升级是NSCLC护理的关键未来方向.